Amyotrophic Lateral Sclerosis Market Poised to Expand at a Robust Pace By 2022

Amyotrophic Lateral Sclerosis (ALS) is a neurological disease that affects nerve cells in the brain
and spinal cords which controls the activity of voluntary muscles. It is also termed as Lou Gehrig’s
disease. There are several causes behind ALS which includes gene mutation, disorganized immune
response, chemical imbalance etc. The symptoms for ALS mainly include fasciculation, respiratory
problems, muscles weakness and cramps. The mortality rate in the ALS patients in high due to
breathing problem. ALS disease is rare and affect 1 or 2 out of 100,000 people across the globe.
Increasing in the number of patients affected with ALS is one of the major factor to drive the
growth of ALS treatment market. Sporadic and familial are two types of ALS disease, in which
sporadic disease is most common disease found with 90–95% of the overall cases in US and the
government initiatives to examination the research for rare disease and FDA approvals creates an
opportunity for various market players due to which the global market of amyotrophic lateral
sclerosis treatment is expected to expand at healthy CAGR during the forecast period. Due to lower
prevalence rate, awareness about the disease and low treatment availability hinder the growth of
ALS treatment market.
Request Report for TOC @ https://www.persistencemarketresearch.com/toc/9626
The competition in the ALS treatment market is weak due to the presence of only one drug in the
market. Riluzole is the only drug which is approved by FDA and dominating the market which
increase the patients survival rate. Also, ALS low efficacy, high cost and moderate safety of therapy
constrains the utilization of the Riluzole drug. Rise in the ageing population worldwide would
enlarge the development of ALS treatment market. The Collaborative ALS Drug Discovery
Initiative (CADDI) and government regulations have taken initiative to accelerate the new drug
development and treatments for ALS, which will further increase the number of pipeline drugs.
Request To Sample of Report @ https://www.persistencemarketresearch.com/samples/9626
Depending on geographic region, amyotrophic lateral sclerosis treatment market is segmented into
five key regions: North America, Latin America, Europe, Asia Pacific and Middle East & Africa.
North America is estimated to contribute maximum revenue share in the global market of
amyotrophic lateral sclerosis treatment followed by Europe. Asia Pacific regions are expected to
grow at a higher growth rate owing to high occurrence of ALS diseases. The developing nations in
Asia Pacific, Middle East and Africa hold huge potential for growth in the global amyotrophic
lateral sclerosis treatment, due to large number of surgical procedures in these regions.
Key players of amyotrophic lateral sclerosis treatment market are GNT Pharma, Amkor Pharma,
Synthetic Biologics, Mitsubishi Tanabe Pharma, Avicena inc, sanofi, and generic versions are
manufactured by Apotex Corp, Mylan Pharmaceuticals Inc, Impax Laboratories.
Pre Book Full Report @ https://www.persistencemarketresearch.com/checkout/9626

The competition in the ALS treatment market is weak due to the presence of only one drug in the market. Riluzole is the only drug which is approved by FDA and dominating the market which increase the patients survival rate. Also, ALS low efficacy, high cost and moderate safety of therapy constrains the utilization of the Riluzole drug. Rise in the ageing population worldwide would enlarge the development of ALS treatment market. The Collaborative ALS Drug Discovery Initiative (CADDI) and government regulations have taken initiative to accelerate the new drug development and treatments for ALS, which will further increase the number of pipeline drugs.

Download Report